Literature DB >> 9333061

Absorption of ofloxacin isomers in the rat small intestine.

L Rabbaa1, S Dautrey, N Colas-Linhart, C Carbon, R Farinotti.   

Abstract

Ofloxacin, a chiral fluoroquinolone, possesses two optical isomers. The antibacterial activity of S-(-)-ofloxacin is 8 to 128 times higher than that of R-(+)-ofloxacin. In the rat, a saturable absorption process has been described for racemic ofloxacin. In the present study we investigated the mechanism underlying the in vivo intestinal absorption of ofloxacin enantiomers in the rat. Blood samples were collected from the portal vein. Our results show that the intestinal absorption of ofloxacin isomers is pH dependent, both enantiomers being best absorbed at neutral pH. S-(-)-Ofloxacin seems to have a greater affinity for the intestinal transporter (initial concentrations at 5 min [C(init)] are 0.17 +/- 0.04 and 0.12 +/- 0.03 microg/ml for S-(-)- and R-(+)-ofloxacin, respectively). Dipeptides fail to modify ofloxacin absorption, but amino acids reduce both isomers' absorption (C(init) is reduced by 53 and 33% with glycine for S-(-)- and R-(+)-ofloxacin, respectively, and by 59 and 42% with L-leucine). Gamma amino butyric acid interferes with the absorption of ofloxacin isomers, but less seriously than do amino acids. Furthermore, ofloxacin competes with other fluoroquinolones or P-glycoprotein substrates for a common secretory pathway, resulting in an increased rate of absorption for both ofloxacin isomers; this is probably an indirect result of their reduced efflux from the apical side of intestinal cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9333061      PMCID: PMC164106     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Absorption of drugs from the rat small intestine.

Authors:  L S SCHANKER; D J TOCCO; B B BRODIE; C A HOGBEN
Journal:  J Pharmacol Exp Ther       Date:  1958-05       Impact factor: 4.030

2.  Method for successive absorptions with intestinal perfusion in vivo.

Authors:  F Ponz; A Ilundain; M Lluch
Journal:  Rev Esp Fisiol       Date:  1979-03

3.  Intestinal drug absorption and metabolism. I. Comparison of methods and models to study physiological factors of in vitro and in vivo intestinal absorption.

Authors:  W H Barr; S Riegelman
Journal:  J Pharm Sci       Date:  1970-02       Impact factor: 3.534

4.  GI absorption of beta-lactam antibiotics I: kinetic assessment of competing absorption and degradation in GI tract.

Authors:  A Tsuji; E Miyamoto; I Kagami; H Sakaguchi; T Yamana
Journal:  J Pharm Sci       Date:  1978-12       Impact factor: 3.534

Review 5.  Absorption of peptide and peptidomimetic drugs.

Authors:  G L Amidon; H J Lee
Journal:  Annu Rev Pharmacol Toxicol       Date:  1994       Impact factor: 13.820

6.  Amoxicillin intestinal absorption reduction by amiloride: possible role of the Na(+) -H+ exchanger.

Authors:  J F Westphal; F Jehl; J M Brogard; C Carbon
Journal:  Clin Pharmacol Ther       Date:  1995-03       Impact factor: 6.875

7.  Optimal perfusion rate determined for in situ intestinal absorption studies in rats.

Authors:  P M Savina; A E Staubus; T S Gaginella; D F Smith
Journal:  J Pharm Sci       Date:  1981-03       Impact factor: 3.534

8.  Intestinal absorption mechanism of amphoteric beta-lactam antibiotics I: Comparative absorption and evidence for saturable transport of amino-beta-lactam antibiotics by in situ rat small intestine.

Authors:  A Tsuji; E Nakashima; I Kagami; T Yamana
Journal:  J Pharm Sci       Date:  1981-07       Impact factor: 3.534

9.  The stimulative effect of diffusion potential on enoxacin uptake across rat intestinal brush-border membranes.

Authors:  T Hirano; K Iseki; S Miyazaki; M Takada; M Kobayashi; M Sugawara; K Miyazaki
Journal:  J Pharm Pharmacol       Date:  1994-08       Impact factor: 3.765

Review 10.  Pefloxacin clinical pharmacokinetics.

Authors:  F Bressolle; F Gonçalves; A Gouby; M Galtier
Journal:  Clin Pharmacokinet       Date:  1994-12       Impact factor: 6.447

View more
  2 in total

1.  Drug discovery and regulatory considerations for improving in silico and in vitro predictions that use Caco-2 as a surrogate for human intestinal permeability measurements.

Authors:  Caroline A Larregieu; Leslie Z Benet
Journal:  AAPS J       Date:  2013-01-24       Impact factor: 4.009

2.  HPLC Method for Determination of Enantiomeric Purity of a Novel Respiratory Fluoroquinolone: WCK 1152.

Authors:  R D Yeole; S V Lawand; S B Bhavsar; P K Deshpande
Journal:  Indian J Pharm Sci       Date:  2008 May-Jun       Impact factor: 0.975

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.